Lipocurc is under clinical development by SignPath Pharma and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Lipocurc’s likelihood of approval (LoA) and phase transition for Prostate Cancer took place on 13 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Lipocurc Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Lipocurc overview

Liposomal curcumin is under development for the treatment of metastatic cancer, advanced solid tumors including non-small cell lung carcinoma, prostate cancer, colon cancer, glioblastoma multiforme, mesothelioma,multiple myeloma, sepsis, Parkinson's disease and coronavirus disease 2019 (COVID-19). The drug candidate is administered through intravenous infusion and acts by targeting HDAC. It is a nanoparticle-sized liposomal formulation.

It was also under development for the treatment of psoriasis, pancreatic cancer and Ebola viral infections.

SignPath Pharma overview

SignPath Pharma develops curcumin based drugs to treat cancer and cardiac side effects. The company is investigating its lead products SPP4040, a cancer supportive care drug to reduce cardiomyopathy caused due to cancer chemotherapy; and LipoCurc, a liposomal synthetic curcumin formulation targeting glioblastoma, multiple myeloma, and other cancer indications. It is also evaluating LipoCurc for the treatment of sepsis and COVID-19. SignPath Pharma utilizes CorreQT, its proprietary platform technology to create lipid based drugs that mitigate cardiac side effects. The company works in partnership with labs, hospitals, and other companies in Canada, Europe, the US, and Asia. SignPath Pharma is headquartered in Sandy, Utah, the US.

Quick View Lipocurc LOA Data

Report Segments
  • Innovator
Drug Name
  • Lipocurc
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Central Nervous System
  • Immunology
  • Infectious Disease
  • Oncology
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.